Provincial Coverage of Generic Semaglutide Uncertain After G7-First Approval

The Approval

Health Canada approved the first generic version of brand-name semaglutide on Tuesday, April 28, 2026, manufactured by Dr. Reddy's Laboratories in India [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/]. The injectable medication is approved for once-a-week treatment of Type 2 diabetes in adults and is sold under the brand name "Obeda" in India [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/]. The application was submitted to Health Canada in early 2024 [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/].

Health Canada has stated that eight other submissions for generic semaglutide are currently under review, with more decisions expected in the coming weeks and months [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/].

Provincial Reimbursement Varies

Federal approval does not automatically translate into provincial drug plan coverage. Dr. Hertzel Gerstein, a professor in the medicine department at McMaster University and a diabetes physician, noted that the process of approving generic GLP-1 drugs into public drug plans differs by province, and it is not yet clear whether generic semaglutide will be covered [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/].

Gerstein explained that while Health Canada approves a drug for the country, individual ministries of health—such as Ontario's, which administers the Ontario Drug Benefit—decide whether to reimburse it, and provinces like Manitoba may make different decisions [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/].

For Wegovy, no Canadian provincial health plan currently provides coverage when the drug is prescribed for weight management, as of January 2026 [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. The Canadian Drug Agency assessed Wegovy's cost-effectiveness in July 2025 and recommended a price reduction, and December 2025 negotiations between the pan-Canadian Pharmaceutical Alliance and Novo Nordisk concluded without agreement [Source: ogaei.ca/blog/wegovy-cost-in-canada/].

How Pricing Could Move

Under the pan-Canadian Pharmaceutical Alliance pricing structure, the first generic version of a medication typically costs 75 to 85 per cent less than the brand name [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/]. Once a second generic enters the market, the price for both typically drops to 50 per cent of brand, and with three or more generics available, the cost typically decreases to about 35 per cent of the brand-name price [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/].

Health Canada has also stated that many generic medications are 45 to 90 per cent cheaper than brand-name versions [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/].

One source reported that the average cost of Ozempic injections can range between $200 and $450 per month depending on province [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/], and that Mounjaro ranges between $300 and $550 per month in Canada [Source: globalnews.ca/news/11820779/canada-approves-1st-generic-ozempic-market/]. Current pharmacy listings on GLP1Prices.ca show wider ranges of $200–$663 for Ozempic and $283.08–$813 for Mounjaro across our verified sample.

Competition Picture

BMO Capital Markets analyst Evan Seigerman said investors will follow the evolution of the market in Canada closely as a test case to see if and how generics can compete with branded peptides [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/]. Seigerman added that Canadian generic entry is likely to remain a localized headwind, with strong U.S. intellectual property protections expected to prevent meaningful spillover [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/].

Swiss generic drugmaker Sandoz has said it plans to launch a generic version of Ozempic in Canada by June this year, positioning itself among the first wave of companies seeking to market copycat versions [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/]. Eli Lilly's Zepbound and Mounjaro continue to gain market share, eroding Novo Nordisk's early first-mover advantage [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/].

Readers tracking application progress can follow our generic semaglutide tracker or use the insurance coverage checker for plan-specific questions, and additional context is available in the FAQ. Information on Rybelsus is also maintained on our drug pages.